课题基金 / 基金详情

Establishment of Rev based anti-HIV therapy.

Establishment of Rev based anti-HIV therapy.
建立基于 Rev 的抗 HIV 疗法。
批准号:
17591037
负责人:
KODAMA Eiichi
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006

项目摘要

项目成果

KODAMA Eiichi的其他基金

相似基金

相关文献

中文摘要
翻译
即使采用广泛联合使用逆转录酶和/或蛋白酶抑制剂的高活性抗逆转录病毒疗法,根除人类免疫缺陷病毒(艾滋病毒)仍有待实现。因此,迫切需要开发新的抑制剂来阻断新的靶点以及逆转录酶或蛋白酶。在这个项目中,首席研究员专注于病毒附属蛋白Rev,这是HIV复制所必需的,并开发了基于肽的Rev抑制剂。研究人员发现含有10到63个Rev转导细胞氨基酸的肽对HIV感染具有抗性,这表明该区域含有HIV抑制肽序列。为了鉴定该区域,构建了包含Rev 10 ~ 63不同大小和区域的肽序列的表达载体。其中含有富含34 ~ 50个氨基酸序列精氨酸的肽具有抑制作用。加入稳定α-螺旋结构的四种丙氨酸增强了抑制效果。人t细胞白血病病毒Rex是Rev的同源物,它也具有富含精氨酸的结构域。该区域对HIV感染也有抑制作用。合成肽也通过其与CXCR4的结合而不是通过抑制Rev功能来阻断HIV感染,这表明需要提高肽渗透细胞的效率。需要进一步的研究来开发临床上有用的Rev抑制剂。
英文摘要
Even under highly active anti-retroviral therapy using extensive combination of inhibitors to reverse transcriptase and/or protease, eradication of human immunodeficiency virus (HIV) remains to be achieved. Thus, development of new inhibitors that block new targets as well as reverse transcriptase or protease is urgently required. In this project, the principal investigator focuses on a viral accessory protein, Rev that is essential for HIV replication and has developed peptide based Rev inhibitors.The investigator found that a peptide containing 10 to 63 amino acids of Rev transduced cells were resistant to HIV infection, suggesting that the region contains an HIV inhibitory peptide sequence. To identify the region, expression vectors containing peptide sequences in various size and region of Rev 10 to 63 were constructed. Among them, a peptide containing arginine rich 34 to 50 amino acid sequence showed inhibitory effect. Addition of four alanines that stabilize α-helical structure enhances the inhibitory effect. Human T-cell leukemia virus Rex, a homolog of Rev also has arginine rich domain. This region also showed inhibitory effect to HIV infection. Synthetic peptides also block HIV infections through its binding to CXCR4, not through suppression of Rev function, indicating that enhancement of peptide penetration efficiency into cells is needed. Further study is needed to develop clinically useful Rev inhibitors.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
A novel colorimetric assay for CXCR4 and CCR5 tropic human immunodeficiency viruses
CXCR4 和 CCR5 热带人类免疫缺陷病毒的新型比色测定
DOI: --
发表时间: 2006
期刊: Antivir Chem Chemother 17
影响因子: --
作者: [Suzuki A, Yamada R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K., Kajiwara K.]
通讯作者: Kajiwara K.
RNase S complex bearing arginine-rich peptide and anti-HIV activity.
RNase S 复合物具有富含精氨酸的肽和抗 HIV 活性。
DOI: --
发表时间: 2004
期刊: J Mol Recognit 18
影响因子: --
作者: [Nakata S, Matsumura I, Tanaka H, Ezoe S, Satoh Y, Ishikawa J, Era T, Kanakura Y., Nameki D, Kitano K, Kohgo S, Hachiya A, Masuda N, Futaki S]
通讯作者: Futaki S
Halogenated thymidine analogs restore the expression of silenced genes without demethylation.
卤化胸苷类似物可恢复沉默基因的表达而不发生去甲基化。
DOI: --
发表时间: 2005
期刊: Cancer Res 65
影响因子: --
作者: [Zhao T, Yasunaga J-I, Satou Y, Nakao M, Takahashi M, Fujii M, Matsuoka M., Suemori K, Shimura K., Mitchell MS., Yoshida M., Hino S., Tajima S., Satou Y., Taniguchi Y., Doi K., Fan J.]
通讯作者: Fan J.
DOI: 10.1021/jm0600139
发表时间: 2006-03-09
期刊: JOURNAL OF MEDICINAL CHEMISTRY
影响因子: 7.3
作者: [Sato, M, Motomura, T, Shinkai, H]
通讯作者: Shinkai, H
共 12 条
    Development of anti-HIV agents that exert synergism with host immune pressure
    • 批准号:
      24390254
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.48万
    • 财政年份:
      2012
    • 负责人:
      KODAMA Eiichi
    • 依托单位:
    Effect of a novel resistance associated mutation, N348I, which has been identified in Japanese HIV-1 infected patients, on the reverse transcriptase activity.
    • 批准号:
      21590591
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.83万
    • 财政年份:
      2009
    • 负责人:
      KODAMA Eiichi
    • 依托单位:
    国内基金
    海外基金
    基于肠道时钟因子REV-ERBα调控PIEZO1节律研究脾肾阳虚泄泻的时辰发作内涵与机制
    • 批准号:
      82574723
    • 项目类别:
      面上项目
    • 资助金额:
      48.00万元
    • 批准年份:
      2025
    • 负责人:
      王帅
    • 依托单位:
    REV3L以不依赖聚合酶活性的方式缓解顺铂损伤的新生物学功能和作用机制研究
    • 批准号:
      32571499
    • 项目类别:
      面上项目
    • 资助金额:
      45.00万元
    • 批准年份:
      2025
    • 负责人:
      李夏璐
    • 依托单位:
    REV1 调控 CGBE 单碱基编辑器的机制及 应用研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2025
    • 负责人:
      梁普平
    • 依托单位:
    生物钟核受体Rev-erbα在肾脏水钠稳态和盐敏感性高血压发生发展中的作用及机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      陈丽红
    • 依托单位: